# PPM1H

## Overview
PPM1H is a gene that encodes the protein phosphatase, Mg2+/Mn2+ dependent 1H, which is a member of the PP2C family of serine/threonine phosphatases. This protein is characterized by its catalytic domain, which is essential for its enzymatic activity, and it plays a significant role in various cellular processes by dephosphorylating specific proteins (Berndsen2019PPM1H). PPM1H is involved in regulating signaling pathways such as the LRRK2 and BMP pathways, impacting cellular functions like autophagy, immune responses, and cilia formation (Shen2014Specific; Berndsen2019PPM1H). The protein's activity is modulated by its substrate-dependent preference for metal ions, favoring Mn2+ or Mg2+ depending on the substrate (Sugiura2009Substratedependent). PPM1H's clinical significance is highlighted by its involvement in cancer and neurological disorders, where alterations in its expression can influence disease progression and treatment outcomes (Xu2019Low; LeeHoeflich2011PPM1H).

## Structure
The PPM1H protein is a member of the PP2C family of serine/threonine phosphatases, characterized by a catalytic domain typical of this family. It consists of 514 amino acid residues and contains a PPM type phosphatase domain, which is essential for its enzymatic activity (Berndsen2019PPM1H). The protein's structure includes several inserts in its sequence, particularly within loops L8 and L13 on the catalytic center side, and loops L2 and L3 on the opposite side. These inserts are mostly conserved among PPM1H and its isoforms PPM1J and PPM1M, except for those in L2. Notably, loop L3 of PPM1H has extra inserts not found in PPM1J or PPM1M, suggesting potential structural differences among these isoforms (Kamada2020Metaldependent).

PPM1H shows substrate-dependent metal ion preference, favoring Mn2+ ions when using p-nitrophenyl phosphate (pNPP) or phosphopeptides as substrates, and Mg2+ ions when casein is the substrate. This preference is attributed to the greater affinity of Mn2+ for PPM1H, which is a common feature among PP2C enzymes (Sugiura2009Substratedependent). The protein is predominantly localized in the cytoplasm and the Golgi apparatus, where it plays a role in dephosphorylating Rab proteins (Berndsen2019PPM1H).

## Function
PPM1H is a serine/threonine phosphatase that plays a crucial role in regulating various cellular processes by dephosphorylating specific proteins. In healthy human cells, PPM1H is involved in counteracting LRRK2 signaling by selectively dephosphorylating Rab proteins, such as Rab8A, Rab8B, Rab10, and Rab35. This activity is significant for maintaining the balance of phosphorylated Rab proteins, which are essential for cellular functions like autophagy, immune responses, and phagosome maturation (Berndsen2019PPM1H).

PPM1H is also implicated in the regulation of cilia formation. Its knockdown suppresses primary cilia formation, similar to the effects of pathogenic LRRK2 mutations, indicating its role in cellular signaling and function (Berndsen2019PPM1H). Additionally, PPM1H is involved in the BMP signaling pathway by dephosphorylating Smad1, thereby inhibiting BMP-mediated transcriptional responses. This regulation is crucial for processes like myogenic differentiation and mesenchymal differentiation, impacting cellular development and tissue formation (Shen2014Specific).

PPM1H is active in the cytoplasm and is localized to the Golgi apparatus, suggesting its involvement in maintaining cellular homeostasis and organismal development (Berndsen2019PPM1H).

## Clinical Significance
Alterations in the expression of the PPM1H gene have been implicated in various diseases, particularly in cancer and neurological disorders. In breast cancer, low expression of PPM1H is associated with trastuzumab resistance in HER2-positive tumors. This resistance is linked to decreased dephosphorylation of p27, a cell cycle inhibitor, leading to increased cell proliferation and poor clinical outcomes (LeeHoeflich2011PPM1H). Similarly, in colorectal cancer, low PPM1H expression correlates with poor prognosis, lower 5-year disease-free survival rates, and increased risk of relapse. This is partly due to its role in activating cancer-associated fibroblasts, which promote tumor growth and invasiveness (Xu2019Low).

In neurological contexts, PPM1H has been studied for its potential role in Parkinson's disease. It dephosphorylates Rab proteins, counteracting LRRK2 signaling, which is involved in autophagy and immune responses. Altered PPM1H activity may influence Parkinson's disease risk by affecting Rab protein phosphorylation (Berndsen2019PPM1H). These findings suggest that PPM1H could serve as a prognostic marker and therapeutic target in various diseases.

## Interactions
PPM1H is a serine/threonine phosphatase that interacts with various proteins, playing a significant role in multiple signaling pathways. It specifically interacts with Smad1/5/8 proteins in the cytoplasm, where it dephosphorylates phosphorylated Smad1/5/8 (P-Smad1/5/8). This interaction is crucial for regulating bone morphogenetic protein (BMP) signaling by preventing the formation of the Smad1-Smad4 complex and its nuclear translocation, thereby inhibiting BMP-mediated transcriptional responses (Shen2014Specific).

PPM1H also interacts with Rab proteins, such as Rab8A, Rab8B, Rab10, and Rab35, which are phosphorylated by LRRK2. PPM1H dephosphorylates these Rab proteins, counteracting LRRK2 signaling. This interaction is important for processes like cilia formation and potentially impacts pathways related to autophagy and immune responses (Berndsen2019PPM1H).

In the context of cancer, PPM1H interacts with the CDK inhibitor p27, dephosphorylating it at the T187 site. This dephosphorylation prevents p27 degradation, stabilizing the protein and inhibiting the cell cycle. This interaction is implicated in trastuzumab resistance in HER2-amplified cancers (LeeHoeflich2011PPM1H).


## References


[1. (Xu2019Low) Xiaowen Xu, Li Zhu, Yun Yang, Yamin Pan, Zhuo Feng, Ye Li, Wenjun Chang, Jinke Sui, and Fuao Cao. Low tumour ppm1h indicates poor prognosis in colorectal cancer via activation of cancer-associated fibroblasts. British Journal of Cancer, 120(10):987–995, April 2019. URL: http://dx.doi.org/10.1038/s41416-019-0450-5, doi:10.1038/s41416-019-0450-5. This article has 10 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/s41416-019-0450-5)

[2. (Shen2014Specific) Tao Shen, Chuang Sun, Zhengmao Zhang, Ningyi Xu, Xueyan Duan, Xin-Hua Feng, and Xia Lin. Specific control of bmp signaling and mesenchymal differentiation by cytoplasmic phosphatase ppm1h. Cell Research, 24(6):727–741, April 2014. URL: http://dx.doi.org/10.1038/cr.2014.48, doi:10.1038/cr.2014.48. This article has 28 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/cr.2014.48)

[3. (Berndsen2019PPM1H) Kerryn Berndsen, Pawel Lis, Wondwossen M Yeshaw, Paulina S Wawro, Raja S Nirujogi, Melanie Wightman, Thomas Macartney, Mark Dorward, Axel Knebel, Francesca Tonelli, Suzanne R Pfeffer, and Dario R Alessi. Ppm1h phosphatase counteracts lrrk2 signaling by selectively dephosphorylating rab proteins. eLife, October 2019. URL: http://dx.doi.org/10.7554/elife.50416, doi:10.7554/elife.50416. This article has 101 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.7554/elife.50416)

[4. (LeeHoeflich2011PPM1H) Si Tuen Lee-Hoeflich, Thinh Q. Pham, Don Dowbenko, Xander Munroe, James Lee, Li Li, Wei Zhou, Peter M. Haverty, Kanan Pujara, Jeremy Stinson, Sara M. Chan, Jeffrey Eastham-Anderson, Ajay Pandita, Somasekar Seshagiri, Klaus P. Hoeflich, Gulisa Turashvili, Karen A. Gelmon, Samuel A. Aparicio, David P. Davis, Mark X. Sliwkowski, and Howard M. Stern. Ppm1h is a p27 phosphatase implicated in trastuzumab resistance. Cancer Discovery, 1(4):326–337, September 2011. URL: http://dx.doi.org/10.1158/2159-8290.cd-11-0062, doi:10.1158/2159-8290.cd-11-0062. This article has 46 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1158/2159-8290.cd-11-0062)

[5. (Kamada2020Metaldependent) Rui Kamada, Fuki Kudoh, Shogo Ito, Itsumi Tani, Jose Isagani B. Janairo, James G. Omichinski, and Kazuyasu Sakaguchi. Metal-dependent ser/thr protein phosphatase ppm family: evolution, structures, diseases and inhibitors. Pharmacology &amp; Therapeutics, 215:107622, November 2020. URL: http://dx.doi.org/10.1016/j.pharmthera.2020.107622, doi:10.1016/j.pharmthera.2020.107622. This article has 65 citations.](https://doi.org/10.1016/j.pharmthera.2020.107622)

[6. (Sugiura2009Substratedependent) Takeyuki Sugiura and Yoshie Noguchi. Substrate-dependent metal preference of ppm1h, a cancer-associated protein phosphatase 2c: comparison with other family members. BioMetals, 22(3):469–477, March 2009. URL: http://dx.doi.org/10.1007/s10534-009-9204-9, doi:10.1007/s10534-009-9204-9. This article has 25 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s10534-009-9204-9)